ArticleSmall science2025
A Kinetic Model of Antigen-Dependent IgG Oligomerization and Complement Binding.
Article in Small science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The classical complement pathway (CCP) is an essential part of the immune system, activated when complement protein C1 binds to IgG antibody oligomers on the surface of pathogens, infected or malignant cells, culminating in the formation of the membrane attack complex and subsequent cell lysis. IgG oligomers also engage immune effector cells through Fcγ receptors or complement receptors, facilitating antibody-dependent cellular cytotoxicity and phagocytosis. Understanding the factors that drive IgG oligomerization is thus crucial for improving IgG-based therapies. Herein, a kinetic model to predict oligomer formation based on IgG concentration, antigen density, IgG subclass, Fc mutants, and oligomerization inhibitors like staphylococcal protein A is developed. The underlying molecular interactions in single molecule force spectroscopy and grating coupled interferometry experiments are characterized. By fitting experimental data from high-speed atomic force microscopy experiments, key rate constants and thermodynamic parameters, including free energy changes associated with oligomerization and apply the model to predict complement-mediated lysis in liposomal vesicle-based assays, are further quantified. The presented mechanistic framework may serve as a basis for optimizing antibody engineering and pharmacokinetic/pharmacodynamic modeling in the context of immunotherapies exploiting the CCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.